Expertise in
6
conditions

Dr. James P. Maynard

Fort Thomas, KY
Expertise in
6
conditions
Specialties:Neurology | Sleep Medicine
Expertise in
6
conditions
OverviewInsuranceLocationsClinical Research

Overview

James Maynard is a Neurologist and a Sleep Medicine provider in Fort Thomas, Kentucky. Dr. Maynard is highly rated in 6 conditions, according to our data. His top areas of expertise are Excessive Daytime Sleepiness, Drowsiness, Obstructive Sleep Apnea, and Familial Hemiplegic Migraine.

His clinical research consists of co-authoring 6 peer reviewed articles and participating in 15 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Neurology
Sleep Medicine
Licenses
Psychiatry & Neurology in KY
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Locations

85 N Grand Ave 6th Fl, Fort Thomas, KY 41075
859-572-3452

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

A Pilot Proof of Concept Pharmacokinetic/Pharmacodynamic Study of BXQ-350 in Cancer Patients Exposed to Oxaliplatin and/or Taxane-Based Chemotherapy
A Pilot Proof of Concept Pharmacokinetic/Pharmacodynamic Study of BXQ-350 in Cancer Patients Exposed to Oxaliplatin and/or Taxane-Based Chemotherapy
Enrollment Status: Completed
Publish Date: January 27, 2025
Intervention Type: Other, Drug
Study Phase: Early Phase 1
A Phase 2, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 mg and 4 mg SUVN-G3031 Compared to Placebo in Patients With Narcolepsy With and Without Cataplexy
A Phase 2, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 mg and 4 mg SUVN-G3031 Compared to Placebo in Patients With Narcolepsy With and Without Cataplexy
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Drug
Study Drug: SUVN-G3031
Study Phase: Phase 2
A Phase 1 Randomized, Blinded, Placebo-controlled Study to Evaluate the Safety and Tolerability of Single and Multiple Ascending Doses of VIB9600 by Intravenous Infusion or Subcutaneous Injection in Healthy Subjects
A Phase 1 Randomized, Blinded, Placebo-controlled Study to Evaluate the Safety and Tolerability of Single and Multiple Ascending Doses of VIB9600 by Intravenous Infusion or Subcutaneous Injection in Healthy Subjects
Enrollment Status: Terminated
Publish Date: December 13, 2024
Intervention Type: Drug, Biological
Study Phase: Phase 1
A Randomized, Double-Blind, Placebo-Controlled, Multiple Rising Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Patients With Narcolepsy With or Without Cataplexy (Narcolepsy Type 1 or Narcolepsy Type 2)
A Randomized, Double-Blind, Placebo-Controlled, Multiple Rising Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Patients With Narcolepsy With or Without Cataplexy (Narcolepsy Type 1 or Narcolepsy Type 2)
Enrollment Status: Terminated
Publish Date: October 29, 2024
Intervention Type: Drug
Study Drug: TAK-994
Study Phase: Phase 2
A Master Protocol to Investigate the Efficacy and Safety of Tirzepatide Once Weekly in Participants Who Have Obstructive Sleep Apnea and Obesity: A Randomized, Double-Blind, Placebo-Controlled Trial
A Master Protocol to Investigate the Efficacy and Safety of Tirzepatide Once Weekly in Participants Who Have Obstructive Sleep Apnea and Obesity: A Randomized, Double-Blind, Placebo-Controlled Trial
Enrollment Status: Completed
Publish Date: May 30, 2024
Intervention Type: Drug
Study Phase: Phase 3
A Dose-Blind Extension Study With Double-blind, Placebo-Controlled, Randomized Withdrawal Period to Evaluate the Safety and Explore the Pharmacokinetics and Pharmacodynamics of TAK-994 in Adults With Narcolepsy With Cataplexy (Narcolepsy Type 1)
A Dose-Blind Extension Study With Double-blind, Placebo-Controlled, Randomized Withdrawal Period to Evaluate the Safety and Explore the Pharmacokinetics and Pharmacodynamics of TAK-994 in Adults With Narcolepsy With Cataplexy (Narcolepsy Type 1)
Enrollment Status: Terminated
Publish Date: December 26, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: November 27, 2023
Intervention Type: Drug
Study Drug: Dihydroergotamine
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome, Followed by an Open Label Extension
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome, Followed by an Open Label Extension
Enrollment Status: Active_not_recruiting
Publish Date: September 14, 2023
Intervention Type: Drug
Study Drug: Pitolisant
Study Phase: Phase 2
Phase 2, Randomized, 3-Period, Placebo-Controlled Crossover Study to Evaluate the Efficacy and Safety in Obstructive Sleep Apnea of AD036 Versus Placebo or Atomoxetine
Phase 2, Randomized, 3-Period, Placebo-Controlled Crossover Study to Evaluate the Efficacy and Safety in Obstructive Sleep Apnea of AD036 Versus Placebo or Atomoxetine
Enrollment Status: Completed
Publish Date: September 14, 2023
Intervention Type: Drug
Study Phase: Phase 2
An Open-Label, 12-Month Study to Evaluate the Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
An Open-Label, 12-Month Study to Evaluate the Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: July 03, 2023
Intervention Type: Drug
Study Drug: Dihydroergotamine
Study Phase: Phase 3
EMERGE: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
EMERGE: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: June 29, 2023
Intervention Type: Drug
Study Phase: Phase 3
Phase 2, Placebo-Controlled, Parallel Group Dose-Finding Study to Evaluate the Efficacy and Safety of Three Dose Levels of AD036 in Adults With Obstructive Sleep Apnea
Phase 2, Placebo-Controlled, Parallel Group Dose-Finding Study to Evaluate the Efficacy and Safety of Three Dose Levels of AD036 in Adults With Obstructive Sleep Apnea
Enrollment Status: Completed
Publish Date: January 17, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Study to Assess the Frequency and Characteristics of Wake and Sleep State Transitions Over Multiple Nights in Subjects With Narcolepsy Type 1 Compared With Healthy Subjects Using a Portable Electroencephalogram Device
A Study to Assess the Frequency and Characteristics of Wake and Sleep State Transitions Over Multiple Nights in Subjects With Narcolepsy Type 1 Compared With Healthy Subjects Using a Portable Electroencephalogram Device
Enrollment Status: Completed
Publish Date: May 07, 2021
Intervention Type: Device
A Phase IIa Randomized, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Bimatoprost in the Treatment of Migraine
A Phase IIa Randomized, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Bimatoprost in the Treatment of Migraine
Enrollment Status: Unknown
Publish Date: April 26, 2019
Intervention Type: Drug
Study Drug: Bimatoprost Topical Solution
Study Phase: Phase 2
A Randomized, Placebo-Controlled, Double-blind, Fixed-Dose, Multiple Cohort, Multiple Crossover, Dose-Finding Study of Oral BTD-001 in Adults With Idiopathic Hypersomnia (IH) or Narcolepsy Type 2
A Randomized, Placebo-Controlled, Double-blind, Fixed-Dose, Multiple Cohort, Multiple Crossover, Dose-Finding Study of Oral BTD-001 in Adults With Idiopathic Hypersomnia (IH) or Narcolepsy Type 2
Enrollment Status: Completed
Publish Date: January 16, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 14 Less Clinical Trials

6 Total Publications

The Combination of Aroxybutynin and Atomoxetine in the Treatment of Obstructive Sleep Apnea (MARIPOSA): A Randomized Controlled Trial.
The Combination of Aroxybutynin and Atomoxetine in the Treatment of Obstructive Sleep Apnea (MARIPOSA): A Randomized Controlled Trial.
Journal: American journal of respiratory and critical care medicine
Published: October 09, 2023
Similar Doctors
Expertise in
79
conditions
Dr. Alberto J. Espay
Neurology
Expertise in
79
conditions
Dr. Alberto J. Espay
Neurology

University Of Cincinnati Physicians Company LLC

3188 Bellevue Ave, 
Cincinnati, OH 
 (4.5 mi)
513-584-1000
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Alberto Espay is a Neurologist in Cincinnati, Ohio. Dr. Espay is highly rated in 79 conditions, according to our data. His top areas of expertise are Parkinson's Disease, Drug Induced Dyskinesia, Focal Dystonia, Conversion Disorder, and Deep Brain Stimulation. Dr. Espay is currently accepting new patients.

Expertise in
6
conditions
Dr. Jennifer R. Molano
Sleep Medicine | Psychiatry | Neurology
Expertise in
6
conditions
Dr. Jennifer R. Molano
Sleep Medicine | Psychiatry | Neurology

University Of Cincinnati Physicians Company LLC

2123 Auburn Ave, 
Cincinnati, OH 
 (4.0 mi)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jennifer Molano is a Sleep Medicine specialist and a Psychiatrist in Cincinnati, Ohio. Dr. Molano is highly rated in 6 conditions, according to our data. Her top areas of expertise are Obstructive Sleep Apnea, Central Sleep Apnea, Cerebellar Degeneration, and Drowsiness. Dr. Molano is currently accepting new patients.

Expertise in
36
conditions
Dr. Andrew P. Duker
Neurology
Expertise in
36
conditions
Dr. Andrew P. Duker
Neurology

University Of Cincinnati Physicians Company LLC

2123 Auburn Ave, 
Cincinnati, OH 
 (4.0 mi)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Andrew Duker is a Neurologist in Cincinnati, Ohio. Dr. Duker is highly rated in 36 conditions, according to our data. His top areas of expertise are Parkinson's Disease, Primary Orthostatic Tremor, Drug Induced Dyskinesia, Chorea, and Deep Brain Stimulation. Dr. Duker is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile